Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 3.

Journal Article

Cornely, Oliver A., Robertson, Michael N., Haider, Shariq, Grigg, Andrew, Geddes, Michelle, Aoun, Mickael, Heinz, Werner J., Raad, Issam, Schanz, Urs, Meyer, Ralf G., Hammond, Sarah P., Mullane, Kathleen M., Ostermann, Helmut, Ullmann, Andrew J., Zimmerli, Stefan, Van Iersel, M. L. P. S., Hepler, Deborah A., Waskin, Hetty, Kartsonis, Nicholas A. and Maertens, Johan (2017). Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease. J. Antimicrob. Chemother., 72 (12). S. 3406 - 3414. OXFORD: OXFORD UNIV PRESS. ISSN 1460-2091

Maertens, Johan ORCID: 0000-0003-4257-5980, Selleslag, Dominik, Heinz, Werner J., Saulay, Mikael, Rahav, Galia, Giladi, Michael, Aoun, Mickael, Kovanda, Laura, Kaufhold, Achim, Engelhardt, Marc, Cornely, Oliver A., Herbrecht, Raoul ORCID: 0000-0002-9381-4876 and Ullmann, Andrew J. (2018). Treatment outcomes in patients with proven/probable vs possible invasive mould disease in a phase III trial comparing isavuconazole vs voriconazole. Mycoses, 61 (11). S. 868 - 877. HOBOKEN: WILEY. ISSN 1439-0507

Maertens, Johan A., Raad, Issam I., Marr, Kieren A., Patterson, Thomas F., Kontoyiannis, Dimitrios P., Cornely, Oliver A., Bow, Eric J., Rahav, Galia, Neofytos, Dionysios ORCID: 0000-0001-6970-2869, Aoun, Mickael, Baddley, John W., Giladi, Michael, Heinz, Werner J., Herbrecht, Raoul ORCID: 0000-0002-9381-4876, Hope, William ORCID: 0000-0001-6187-878X, Karthaus, Meinolf, Lee, Dong-Gun ORCID: 0000-0003-4655-0641, Lortholary, Olivier, Morrison, Vicki A., Oren, Ilana, Selleslag, Dominik, Shoham, Shmuel, Thompson, George R., III, Lee, Misun, Maher, Rochelle M., Schmitt-Hoffmann, Anne-Hortense, Zeiher, Bernhardt and Ullmann, Andrew J. (2016). Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet, 387 (10020). S. 760 - 770. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1474-547X

This list was generated on Sat Jan 16 01:45:58 2021 CET.